Is Semaglutide Safe? Evidence, Risks and When to Get Help

What the regulators and trials found about semaglutide's safety record

The MHRA assessed semaglutide's full clinical dossier before licensing Wegovy in the UK. The STEP 1 trial (the cornerstone of that evidence base, published in the New England Journal of Medicine) reported around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose, with a side-effect profile that the investigators described as consistent and manageable. Most adverse events were gastrointestinal and were most pronounced in the first weeks of treatment, particularly around dose increases. They generally eased as participants' systems adapted.

NICE reviewed the same body of evidence before issuing its recommendation (TA875), and the NHS has since incorporated semaglutide into its medicines-for-obesity commissioning. That chain of scrutiny (manufacturer, MHRA, NICE, NHS) does not guarantee that every person will tolerate the medicine without difficulty, but it does mean the question of semaglutide's safety has been answered in a rigorous, systematic way, not just by manufacturer claims.

The ongoing Black Triangle (▼) designation means the MHRA continues to collect post-marketing data. New safety signals, when they emerge, are reviewed promptly. The January 2026 MHRA Drug Safety Update on GLP-1 medicines, for example, drew attention to acute pancreatitis as a known but infrequent risk, highlighting that the regulatory machinery is actively working, not dormant. You can read about the full Wegovy side-effect profile in more detail elsewhere on our site.

The side effects people actually experience day to day

Nausea is the one most patients mention first. It tends to peak in the days after a dose increase and then retreat; for many people it largely disappears by the time they reach their maintenance dose. Constipation, loose stools, reflux and low-level fatigue are also in the common bracket. None of these are trivial to live with, but they are predictable and temporary for most people. The NHS semaglutide medicines page lists them clearly and is worth bookmarking.

Less common but worth knowing: some people experience headaches, dizziness, or injection-site reactions. These generally respond to practical adjustments, rotating the injection site, staying well hydrated, eating smaller meals more frequently during the early weeks. Specific instructions always sit in the Patient Information Leaflet that comes with your pen; if you are thinking about the wider question of how safe semaglutide is over the longer term, our dedicated page covers that in full.

One thing our prescribers hear regularly: people are more anxious about side effects before they start than after a few weeks on the medicine. That does not mean the side effects are trivial, it means they are usually manageable with the right support and a gradual titration schedule set by a qualified prescriber.

When to get medical help without delay

Most side effects do not require a trip to A&E. Some do. The MHRA's January 2026 Drug Safety Update specifically flagged acute pancreatitis: if you develop severe abdominal pain that radiates to your back, with or without vomiting, stop the medicine and seek urgent medical attention. This is rare, but it can be serious.

Other symptoms that should prompt you to seek help promptly include: signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, a widespread rash), significant dehydration from vomiting or diarrhoea that you cannot manage at home, and any sudden changes in mood, low mood, or thoughts of self-harm. If you are unsure whether it is safe to take semaglutide alongside your existing conditions or medicines, contact your prescribing service before making any changes. At nume, our aftercare team is available seven days a week, you can reach us via the contact page. If it is urgent, call 111 or 999. And if you experience something unexpected that you think others should know about, you can report it to the MHRA through the Yellow Card scheme; that data feeds directly into ongoing safety monitoring.

Who semaglutide is and is not appropriate for

How safe semaglutide is for any individual depends partly on their health history. The licensed indication covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or raised cholesterol. But licensing criteria are a floor, not a rubber stamp. Prescribers also consider contraindications: a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and certain gastrointestinal conditions all warrant careful discussion before starting.

Semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. Women using oral contraceptives should discuss contraception with their prescriber before starting; if you have questions specific to the branded injectable, our page looking at whether Wegovy is safe covers those considerations alongside the NHS England guidance on weight-management injections, including the advice to consider non-oral contraceptive methods during treatment.

If you are coming to semaglutide from another provider, or considering it for the first time, the question of whether it is appropriate for you specifically is answered through a clinical consultation. Our prescribers go through suitability, side effects and your personal history as a matter of course, not as a formality. If you'd like that conversation, you can start your free consultation today. There is no obligation, and no same-day pressure; plenty of people submit their consultation on a quiet Tuesday evening or before the bank holiday and hear back when our prescribers are next reviewing.